SCHEMBL4377989

SCHEMBL4377989

Cc1cc(O)c(Br)c(=O)n1Cc1cccnc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SRC P12931 1/20 0.51
GABRA1 P14867 5/20 0.46
GABRA5 P31644 5/20 0.46
PKM P14618 2/20 0.46
MEN1 O00255 1/20 0.46
CYP1A2 P05177 1/20 0.46
CYP3A4 P08684 1/20 0.46
CYP2D6 P10635 1/20 0.46
CYP2C9 P11712 1/20 0.46
CYP2C19 P33261 1/20 0.46
KMT2A Q03164 1/20 0.46
BRD4 O60885 1/20 0.46
COMT P21964 1/20 0.44
NOX4 Q9NPH5 2/20 0.43
ALDH1A1 P00352 2/20 0.43
CYBB P04839 1/20 0.43
GRIN1 Q05586 1/20 0.43
GRIN2B Q13224 1/20 0.43
LMNA P02545 1/20 0.43
CASP1 P29466 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4384391 0.85 SRC (0.51) SRCGABRA1GABRA5PKMKMT2A
SCHEMBL4387870 0.84 MEN1 (0.51) PKMMEN1KMT2ABRD4ALDH1A1
SCHEMBL4382351 0.84 ALDH1A1 (0.50) SRCMEN1KMT2AALDH1A1LMNA
SCHEMBL4468385 0.81 KDM4E (0.53) GABRA1GABRA5PKMMEN1CYP1A2
SCHEMBL4376936 0.80 LMNA (0.52) SRCGABRA1GABRA5PKMBRD4
SCHEMBL4379494 0.78 KDM4E (0.58) PKMALDH1A1LMNAHSD17B10
SCHEMBL4380789 0.77 NPSR1 (0.47) GABRA1GABRA5PKMMEN1CYP1A2
SCHEMBL4379935 0.76 MAPK14 (0.43) GABRA1GABRA5PKMMEN1CYP1A2
SCHEMBL4385215 0.76 NPSR1 (0.48) GABRA1GABRA5PKMMEN1CYP1A2
SCHEMBL4373618 0.76 MAPK14 (0.70) PKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7629363-B2 antiinflammatory agent for treating asthma and chronic pulmonary inflammatory disease PFIZER INC (US) 2009-12-08 US disclosed
US-7629363-B2 antiinflammatory agent for treating asthma and chronic pulmonary inflammatory disease PFIZER INC (US) 2009-12-08 US disclosed
US-7629363-B2 antiinflammatory agent for treating asthma and chronic pulmonary inflammatory disease PFIZER INC (US) 2009-12-08 US disclosed
EP-1490064-B1 SUBSTITUTED PYRIDINONES AS MODULATORS OF P38 MAP KINASE PHARMACIA CORP (US) 2009-11-18 EP disclosed
EP-1490064-B1 SUBSTITUTED PYRIDINONES AS MODULATORS OF P38 MAP KINASE PHARMACIA CORP (US) 2009-11-18 EP disclosed
US-7067540-B2 Substituted pyridinones PHARMACIA CORPORATION (US) 2006-06-27 US disclosed
US-20050176775-A1 Substituted pyridinones PHARMACIA CORPORATION 2005-08-11 US disclosed
WO-2005018557-A2 SUBSTITUTED PYRIDINONES PHARMACIA CORPORATION (US) 2005-03-03 WO disclosed
US-20040058964-A1 Substituted pyridinones PHARMACIA LLC 2004-03-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040058964-A1 Substituted pyridinones MAPK1, MAPK6, MAPK7 SRC 1152/4885GABRA1 4010/4885GABRA5 3808/4885
US-20050176775-A1 Substituted pyridinones MAPK1, MAPK6, MAP3K6 SRC 1454/4885GABRA1 3767/4885GABRA5 3836/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.